Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss ...

Novo Nordisk says Hims & Hers' drugs breach its patent; Hims & Hers calls the lawsuit a "blatant attack".

Hims & Hers unlawfully mass markets unapproved versions of Novo Nordisk’s FDA-approved semaglutide medicines, deceiving patients and putting ...

Analysts consider AtaiBeckley’s MDMA candidate a “high-risk, high-reward” bet after the drug demonstrated reductions in ...

Almost £150bn has been wiped off Ozempic drugmaker Novo Nordisk after a trial of its new weight-loss drug fell short of ...

Novo Nordisk will set a $675/month US list price (effective January 1, 2027) for Wegovy, Ozempic, and Rybelsus, targeting affordability for high-deductible and coinsurance designs. Impacted doses ...

Hims & Hers has withdrawn its $49 compounded semaglutide pill after pressure from top U.S. health officials at the FDA and HHS. The company now faces a lawsuit from Novo Nordisk for patent ...

Letter writers rebut candidate's letter criticizing ICE, propose a statue at Gilley's, endorse local candidates and more.

Novo Nordisk has sued Hims & Hers for patent infringement, saying the online site is selling cheaper, unapproved copies of the Wegovy weight loss drug ...

Mexico is one of three countries co-hosting this year's World Cup, which officially kicks off in June ...